Under the agreement, Candid Therapeutics will hold global rights to a preclinical trispecific antibody discovered at WUXI BIO's proprietary universal multispecific antibody platform WuXiBody.

Candid Therapeutics Inc. has entered into an agreement with Wuxi Biologics Co. Ltd. under which Candid will have exclusive global rights to a preclinical trispecific T-cell engager discovered by ...

Developed using Simcere’s T-cell engager ... multi-specific biologic candidates in the fields of oncology and immunology. "AbbVie and Simcere Zaiming link to develop trispecific antibody ...

US-based Candid Therapeutics has signed another T-cell engager (TCE ... Candid will have exclusive global rights to a tri-specific TCE discovered by WuXi using its WuXiBody platform.

The asset in question is a trispecific T-cell engager developed by WuXi’s multispecific antibody platform WuXiBody. Candid is eyeing getting the candidate into the clinic in the first half of 2026.

developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform. This molecule features a low affinity/high target-activating CD3 engaging arm and ...

with then-CEO Richard Gonzalez telling analysts back in 2023 that the BCMA bispecific antibody T-cell engager ABBV-383 was driving the company’s “high level of interest” in the space.

(“Candid”), a clinical-stage biotechnology company focused on becoming the leader in advancing T ... T-cell Engager discovered at WuXi Biologics’ proprietary universal multispecific antibody ...

giving Candid exclusive global rights to a preclinical trispecific T-cell engager discovered on WuXi Biologics’ proprietary universal multispecific antibody platform WuXiBody™. WuXi Biologics ...

SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3, developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform.